Your browser doesn't support javascript.
loading
Protein nanovaccine confers robust immunity against Toxoplasma.
El Bissati, Kamal; Zhou, Ying; Paulillo, Sara Maria; Raman, Senthil Kumar; Karch, Christopher P; Roberts, Craig W; Lanar, David E; Reed, Steve; Fox, Chris; Carter, Darrick; Alexander, Jeff; Sette, Alessandro; Sidney, John; Lorenzi, Hernan; Begeman, Ian J; Burkhard, Peter; McLeod, Rima.
Afiliação
  • El Bissati K; Departments of OVS, The University of Chicago, 5841S Maryland Ave, Chicago, IL 60637 USA.
  • Zhou Y; Departments of OVS, The University of Chicago, 5841S Maryland Ave, Chicago, IL 60637 USA.
  • Paulillo SM; Alpha-O Peptides AG, Lörracherstrasse 50, 4125 Riehen, Switzerland.
  • Raman SK; Alpha-O Peptides AG, Lörracherstrasse 50, 4125 Riehen, Switzerland.
  • Karch CP; Institute of Materials Science and Department of Molecular and Cell Biology, University of Connecticut, 97 North Eagleville Road, Storrs, CT 06269 USA.
  • Roberts CW; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE UK.
  • Lanar DE; Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
  • Reed S; Infectious Diseases Research Institute, 1616 Eastlake Ave E #400, Seattle, WA 98102 USA.
  • Fox C; Infectious Diseases Research Institute, 1616 Eastlake Ave E #400, Seattle, WA 98102 USA.
  • Carter D; Infectious Diseases Research Institute, 1616 Eastlake Ave E #400, Seattle, WA 98102 USA.
  • Alexander J; PaxVax, 3985-A Sorrento Valley Blvd, San Diego, CA 92121 USA.
  • Sette A; La Jolla Institute of Allergy and Immunology, 9420 Athena Cir, La Jolla, CA 92037 USA.
  • Sidney J; La Jolla Institute of Allergy and Immunology, 9420 Athena Cir, La Jolla, CA 92037 USA.
  • Lorenzi H; J. Craig Venter Institute, 9714 Medical Center Drive, Rockville, MD 20850 USA.
  • Begeman IJ; Departments of OVS, The University of Chicago, 5841S Maryland Ave, Chicago, IL 60637 USA.
  • Burkhard P; Alpha-O Peptides AG, Lörracherstrasse 50, 4125 Riehen, Switzerland.
  • McLeod R; Institute of Materials Science and Department of Molecular and Cell Biology, University of Connecticut, 97 North Eagleville Road, Storrs, CT 06269 USA.
NPJ Vaccines ; 2: 24, 2017.
Article em En | MEDLINE | ID: mdl-29263879
ABSTRACT
We designed and produced a self-assembling protein nanoparticle. This self-assembling protein nanoparticle contains five CD8+ HLA-A03-11 supertypes-restricted epitopes from antigens expressed during Toxoplasma gondii's lifecycle, the universal CD4+ T cell epitope PADRE, and flagellin as a scaffold and TLR5 agonist. These CD8+ T cell epitopes were separated by N/KAAA spacers and optimized for proteasomal cleavage. Self-assembling protein nanoparticle adjuvanted with TLR4 ligand-emulsion GLA-SE were evaluated for their efficacy in inducing IFN-γ responses and protection of HLA-A*1101 transgenic mice against T. gondii. Immunization, using self-assembling protein nanoparticle-GLA-SE, activated CD8+ T cells to produce IFN-γ. Self-assembling protein nanoparticle-GLA-SE also protected HLA-A*1101 transgenic mice against subsequent challenge with Type II parasites. Hence, combining CD8+ T cell-eliciting peptides and PADRE into a multi-epitope protein that forms a nanoparticle, administered with GLA-SE, leads to efficient presentation by major histocompatibility complex Class I and II molecules. Furthermore, these results suggest that activation of TLR4 and TLR5 could be useful for development of vaccines that elicit T cells to prevent toxoplasmosis in humans.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: NPJ Vaccines Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: NPJ Vaccines Ano de publicação: 2017 Tipo de documento: Article